207 related articles for article (PubMed ID: 35872552)
1. Comparison of serum tryptase as a diagnostic oncological marker in canine versus human mast cell neoplasms.
De Vos S; Demeyere K; De Cock H; Devriendt N; Schwarzkopf I; Fortrie R; Roggeman T; Meyer E; De Spiegelaere W; de Rooster H
Res Vet Sci; 2022 Dec; 151():90-95. PubMed ID: 35872552
[TBL] [Abstract][Full Text] [Related]
2. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors.
Kiupel M; Webster JD; Kaneene JB; Miller R; Yuzbasiyan-Gurkan V
Vet Pathol; 2004 Jul; 41(4):371-7. PubMed ID: 15232137
[TBL] [Abstract][Full Text] [Related]
3. Mutation and methylation status of KIT and TP
Vozdova M; Kubickova S; Fictum P; Cernohorska H; Fröhlich J; Rubes J
Vet Comp Oncol; 2020 Sep; 18(3):438-444. PubMed ID: 31574575
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and prognostic value of c-kit and TP53 mutations in canine mast cell tumours.
Vozdova M; Kubickova S; Fictum P; Fröhlich J; Jelinek F; Rubes J
Vet J; 2019 May; 247():71-74. PubMed ID: 30971355
[TBL] [Abstract][Full Text] [Related]
5. Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication.
Webster JD; Yuzbasiyan-Gurkan V; Miller RA; Kaneene JB; Kiupel M
Vet Pathol; 2007 May; 44(3):298-308. PubMed ID: 17491070
[TBL] [Abstract][Full Text] [Related]
6. c-KIT messenger RNA and protein expression and mutations in canine cutaneous mast cell tumors: correlations with post-surgical prognosis.
Giantin M; Vascellari M; Morello EM; Capello K; Vercelli A; Granato A; Lopparelli RM; Nassuato C; Carminato A; Martano M; Mutinelli F; Dacasto M
J Vet Diagn Invest; 2012 Jan; 24(1):116-26. PubMed ID: 22362941
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone.
Webster JD; Yuzbasiyan-Gurkan V; Thamm DH; Hamilton E; Kiupel M
BMC Vet Res; 2008 Aug; 4():32. PubMed ID: 18700956
[TBL] [Abstract][Full Text] [Related]
8. The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs.
Gentilini F; Turba ME; Dally C; Takanosu M; Kurita S; Bonkobara M
BMC Vet Res; 2020 Feb; 16(1):64. PubMed ID: 32075643
[TBL] [Abstract][Full Text] [Related]
9. Differences in the proteome of high-grade versus low-grade canine cutaneous mast cell tumours.
Schlieben P; Meyer A; Weise C; Bondzio A; Einspanier R; Gruber AD; Klopfleisch R
Vet J; 2012 Nov; 194(2):210-4. PubMed ID: 22578690
[TBL] [Abstract][Full Text] [Related]
10. All subunits of the interleukin-2 receptor are expressed by canine cutaneous mast cell tumours.
Meyer A; Gruber AD; Klopfleisch R
J Comp Pathol; 2013 Jul; 149(1):19-29. PubMed ID: 23276382
[TBL] [Abstract][Full Text] [Related]
11. Expression of Phosphorylated KIT in Canine Mast Cell Tumor.
Halsey CHC; Thamm DH; Weishaar KM; Burton JH; Charles JB; Gustafson DL; Avery AC; Ehrhart EJ
Vet Pathol; 2017 May; 54(3):387-394. PubMed ID: 28129097
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors.
Webster JD; Kiupel M; Yuzbasiyan-Gurkan V
BMC Cancer; 2006 Apr; 6():85. PubMed ID: 16579858
[TBL] [Abstract][Full Text] [Related]
13. Carboxypeptidase A3 expression in canine mast cell tumors and tissue-resident mast cells.
Hämäläinen S; Kareinen L; Sukura A; Kareinen I
Vet Pathol; 2022 Mar; 59(2):236-243. PubMed ID: 34894899
[TBL] [Abstract][Full Text] [Related]
14. C-kit as a prognostic and therapeutic marker in canine cutaneous mast cell tumours: From laboratory to clinic.
Gil da Costa RM
Vet J; 2015 Jul; 205(1):5-10. PubMed ID: 26021891
[TBL] [Abstract][Full Text] [Related]
15. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
[TBL] [Abstract][Full Text] [Related]
16. Histologic grading of canine mast cell tumor: is 2 better than 3?
Sabattini S; Scarpa F; Berlato D; Bettini G
Vet Pathol; 2015 Jan; 52(1):70-3. PubMed ID: 24513799
[TBL] [Abstract][Full Text] [Related]
17. CD25 is expressed by canine cutaneous mast cell tumors but not by cutaneous connective tissue mast cells.
Meyer A; Gruber AD; Klopfleisch R
Vet Pathol; 2012 Nov; 49(6):988-97. PubMed ID: 22446323
[TBL] [Abstract][Full Text] [Related]
18. Expression of Ki67, BCL-2, and COX-2 in canine cutaneous mast cell tumors: association with grading and prognosis.
Vascellari M; Giantin M; Capello K; Carminato A; Morello EM; Vercelli A; Granato A; Buracco P; Dacasto M; Mutinelli F
Vet Pathol; 2013 Jan; 50(1):110-21. PubMed ID: 22673539
[TBL] [Abstract][Full Text] [Related]
19. An immunohistochemical study of vitamin D receptor expression in canine cutaneous mast cell tumours.
Russell DS; Rassnick KM; Erb HN; Vaughan MM; McDonough SP
J Comp Pathol; 2010; 143(2-3):223-6. PubMed ID: 20334872
[TBL] [Abstract][Full Text] [Related]
20. Mastocytosis in the skin in dogs: A multicentric case series.
Wyatt EK; Affolter V; Borio S; Guillen A; Verganti S; Murphy S; Ballarini D; Banovic F; Schmidt V; Tanis JB
Vet Comp Oncol; 2024 Mar; 22(1):136-148. PubMed ID: 38243867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
